Article
Immunology
Juliette Romaru, Mathilde Bahuaud, Gauthier Lejeune, Maxime Hentzien, Jean-Luc Berger, Ailsa Robbins, Delphine Lebrun, Yohan N'Guyen, Firouze Bani-Sadr, Frederic Batteux, Amelie Servettaz
Summary: This study evaluated the immunological response and protection in HIV patients with a CD4 cell count above 200 cells/μL after receiving a single dose of PCV13. The results showed that PCV13 induced immune response and protection in these patients at one month, and over half of the patients remained immunologically protected at one year after vaccination.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biotechnology & Applied Microbiology
Wenjuan Wang, Qi Liang, Jiahong Zhu, Junxia Zhang, Junsheng Chen, Sulan Xie, Yuemei Hu, Guifan Li
Summary: This study evaluated the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13). The results showed that PCV13 had non-inferior immunogenicity and a good safety profile compared to the control vaccine.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Immunology
Yan Li, Huaqing Wang, Wesley Furnback, Bruce C. M. Wang, Shuiqing Zhu, Peng Dong
Summary: The study found that vaccinating infants with PCV13 in cities like Beijing, Shanghai, Shenzhen, Chengdu, Karamay, Qingdao, and Suzhou is a cost-effective strategy, especially when considering both direct and indirect effects. Vaccination has significant benefits for infant health and improves quality of life while remaining cost-effective.
Article
Immunology
Nathorn Chaiyakunapruk, Dayoung Song, Julia Lynch, Jerome H. Kim, Piyameth Dilokthornsakul, Tawee Chotpitayasunondh, Vittal Mogasale
Summary: This study evaluates the potential cost-effectiveness of introducing PCV 12 vaccine in Thailand. The results show that the national PCV12 vaccination program is a cost-saving strategy compared to no vaccination, and has potential public health value.
Article
Immunology
Karen S. Tiley, Helen Ratcliffe, Merryn Voysey, Kimberley Jefferies, Gemma Sinclair, Melanie Carr, Rachel Colin-Jones, David Smith, Jaclyn Bowman, Thomas Hart, Rama Kandasamy, Jason Hinds, Katherine Gould, Guy Berbers, Irina Tcherniaeva, Hannah Robinson, Emma Plested, Parvinder Aley, Matthew D. Snape
Summary: Pneumococcal carriage in children aged 13-48 months remained stable between 2014-2015 and 2017-2019, both overall and for individual serotypes, with the exception of an increase in serotype 7C. More than 20% of children carried the additional serotypes contained in PCV20.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Pediatrics
Natalie Banniettis, Michael Horn, Manish M. Sadarangani, Shrita M. Patel, David Greenberg, Peninnah P. Oberdorfer, Nicola P. Klein, Richard Rupp, Ron Dagan, Peter Richmond, Jessie Lumley, Wei Zhou, Yaru Shi, Gretchen Tamms, Kristen Feemster, Robert Lupinacci, Luwy Musey, Kara Bickham
Summary: This study evaluated the safety and tolerability of V114 in infants. The results showed that the proportions of participants with adverse events were generally comparable between recipients of V114 and PCV13. Most adverse events were mild-to-moderate in intensity and lasted no more than 3 days. These study results support routine use of V114 in infants.
Article
Immunology
Asia -Sophia Wolf, Elena Mitsi, Scott Jones, Simon P. Jochems, Lucy Roalfe, Deus Thindwa, James E. Meiring, Jacquline Msefula, Farouck Bonomali, Tikhala Makhaza Jere, Maurice Mbewe, Andrea M. Collins, Stephen B. Gordon, Melita A. Gordon, Daniela M. Ferreira, Neil French, David Goldblatt, Robert S. Heyderman, Todd D. Swarthout
Summary: This study investigates the protective mechanism of childhood pneumococcal conjugate vaccine (PCV) against pneumococcal carriage. The results show no clear relationship between antibody quality and protection from carriage, suggesting that PCV13-driven antibody quality may mature with age and exposure.
Article
Immunology
Haruka Maeda, Bhim Gopal Dhoubhadel, Eiichiro Sando, Motoi Suzuki, Akitsugu Furumoto, Norichika Asoh, Makito Yaegashi, Masahiro Aoshima, Masayuki Ishida, Sugihiro Hamaguchi, Yoshihito Otsuka, Konosuke Morimoto
Summary: The introduction of pediatric pneumococcal conjugate vaccines (PCVs) in Japan has reduced pneumococcal pneumonia and invasive disease caused by PCV-covered serotypes among children and adults. However, the long-term impact of PCV use in children on adult pneumococcal pneumonia in Japan remains unclear.
Article
Immunology
Kevin Cannon, Charles Elder, Mariano Young, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William C. Gruber, Wendy Watson
Summary: The study demonstrated that PCV20 is well tolerated and immunogenic in adults over 65 years of age with a history of different pneumococcal vaccine regimens, showing robust immune responses to the 20 vaccine serotypes a month after vaccination.
Article
Biotechnology & Applied Microbiology
Randall Severance, Howard Schwartz, Ron Dagan, Laurie Connor, Jianing Li, Alison Pedley, Jonathan Hartzel, Tina M. Sterling, Katrina M. Nolan, Gretchen M. Tamms, Luwy K. Musey, Ulrike K. Buchwald
Summary: This study evaluated the safety and efficacy of concomitant administration of V114 pneumococcal conjugate vaccine and quadrivalent influenza vaccine in healthy adults aged 50 and older. The results showed that there was no difference in immunogenicity between the concomitant and non-concomitant groups, supporting the coadministration of these two vaccines.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Pediatrics
Larisa Savrasova, Angelika Krumina, Hedija Cupeca, Indra Zeltina, Anita Villerusha, Ilze Grope, Ludmila Viksna, Elina Dimina, Sooria Balasegaram
Summary: From 2012 to 2018, 466 cases of IPD were reported in Latvia. The highest incidence was in 2015 at 4.4/100,000, which decreased to 3.9 in 2018. PCV10 vaccine serotypes were the most prevalent in IPD cases, while non-vaccine serotypes showed an increasing trend. The overall case fatality rate was 19%, with Streptococcus pneumoniae serotype 3 associated with fatal IPD outcome. Further studies on S. pneumoniae carriage are needed to understand serotype circulation.
FRONTIERS IN PEDIATRICS
(2021)
Article
Immunology
Ron Dagan, Bart Adriaan van der Beek, Shalom Ben-Shimol, Tamara Pilishvili, Noga Givon-Lavi
Summary: The study demonstrates that the 7-valent and 13-valent pneumococcal vaccines are effective in protecting against otitis media caused by specific serotypes, especially serotypes 19F and 19A.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Biotechnology & Applied Microbiology
Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson
Summary: This study evaluated the safety and immune response of coadministering or separating cPCV7 and PCV13 in infants. The results showed that cPCV7 can be coadministered or separated from PCV13 without immunologic interference, and can induce a robust immune response. These findings support the use of a complementary PCV to supplement existing PCVs.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Article
Immunology
Carlo Casanova, Marianne Kuffer, Stephen L. Leib, Markus Hilty
Summary: In Switzerland during the first six months of 2021, the incidence of invasive pneumococcal disease rebounded as COVID-19 measures were relaxed, with the emergence of non-vaccine type serotype 23B which is associated with reduced susceptibility to penicillin. This highlights the importance of monitoring and addressing potential changes in disease patterns in the context of ongoing public health crises.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Biochemistry & Molecular Biology
Rahul Ahuja, Asha Shelly, Jairam Meena, Amulya K. Panda
Summary: Protein-based vaccines are a safe and affordable strategy for combating pneumococcal disease. The study shows that using biodegradable polymer microparticles can improve the immunogenicity of the pneumococcal protein SP0845, resulting in higher antibody response and better temperature stability compared to traditional adjuvanted protein vaccines.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Infectious Diseases
Alessandro Miglietta, Francesco Innocenti, Patrizio Pezzotti, Eleonora Riccobono, Maria Moriondo, Patrizia Pecile, Francesco Nieddu, Gian Maria Rossolini, Chiara Azzari, Emanuela Balocchini, Giovanni Rezza, Fabio Voller, Paola Stefanelli, Alessandra Bagnoli, Giuseppe Boncompagni, Francesco Cipriani, Paolo Filidei, Giorgio Garofalo, Marinella Chiti, Gabriele Mazzoni, Astrid Mercone, Giovanna Mereu, Sabrina Novelli, Maria Grazia Santini, Maurizio Spagnesi
BMC INFECTIOUS DISEASES
(2019)
Article
Allergy
Francesca Mori, Giulia Liccioli, Alessandra Piccorossi, Lucrezia Sarti, Simona Barni, Mattia Giovannini, Chiara Azzari, Mariangela Manfredi, Elio Novembre
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
(2019)
Article
Pediatrics
Fernando M. de Benedictis, Ines Carloni, Patrizia Osimani, Giovanni Cobellis, Ascanio Martino, Cecilia Lanza, Antonio A. Niccoli, Chiara Azzari, Edlira Skrami, Rosaria Gesuita
PEDIATRIC PULMONOLOGY
(2019)
Article
Multidisciplinary Sciences
Sara Guiducci, Maria Moriondo, Francesco Nieddu, Silvia Ricci, Elisa De Vitis, Arianna Casini, Giovanni Maria Poggi, Giuseppe Indolfi, Massimo Resti, Chiara Azzari
Article
Allergy
Davide Montin, Agostina Marolda, Francesco Licciardi, Francesca Robasto, Silvia Di Cesare, Emanuela Ricotti, Francesca Ferro, Giacomo Scaioli, Carmela Giancotta, Donato Amodio, Francesca Conti, Giuliana Giardino, Lucia Leonardi, Silvia Ricci, Stefano Volpi, Lucia Augusta Baselli, Chiara Azzari, Grazia Bossi, Rita Consolini, Rosa Maria Dellepiane, Marzia Duse, Marco Gattorno, Baldassarre Martire, Maria Caterina Putti, Annarosa Soresina, Alessandro Plebani, Ugo Ramenghi, Silvana Martino, Claudio Pignata, Caterina Cancrini
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2019)
Article
Pharmacology & Pharmacy
Maura Calvani, Gennaro Bruno, Massimo Dal Monte, Romina Nassini, Filippo Fontani, Arianna Casini, Lorenzo Cavallini, Matteo Becatti, Francesca Bianchini, Francesco De Logu, Giulia Forni, Giancarlo la Marca, Lido Calorini, Paola Bagnoli, Paola Chiarugi, Alberto Pupi, Chiara Azzari, Pierangelo Geppetti, Claudio Favre, Luca Filippi
BRITISH JOURNAL OF PHARMACOLOGY
(2019)
Article
Immunology
Chiara Azzari, Daniele Serranti, Francesco Nieddu, Maria Moriondo, Arianna Casini, Lorenzo Lodi, Fernando M. de Benedictis, Elisa De Vitis, Federica Cavone, Martina Cortimiglia, Giuseppe Indolfi, Enrico Lombardi, Ines Carloni, Renato Cutrera, Ersilia Lucenteforte, Massimo Resti, Silvia Ricci
Article
Allergy
Clementina Canessa, Vera Gallo, Claudio Pignata, Antonino Trizzino, Simona Graziani, Baldassarre Martire, Viviana Moschese, Valentina Palladino, Giorgio Maria Boggia, Andrea Matucci, Antonio Pecoraro, Giuseppe Spadaro, Alessandra Vultaggio, Chiara Azzari
PEDIATRIC ALLERGY IMMUNOLOGY AND PULMONOLOGY
(2019)
Article
Obstetrics & Gynecology
Giulia Remaschi, Silvia Ricci, Martina Cortimiglia, Elisa De Vitis, Laura Iannuzzi, Luca Boni, Chiara Azzari, Carlo Dani
Summary: TREC and KREC levels are lower in preterm infants compared to term infants, but this does not increase the risk of neonatal sepsis.
JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE
(2021)
Article
Immunology
Federica Barbati, Maria Moriondo, Laura Pisano, Elisa Calistri, Lorenzo Lodi, Silvia Ricci, Mattia Giovannini, Clementina Canessa, Giuseppe Indolfi, Chiara Azzari
Review
Immunology
Adriano Arguedas, Krzysztof Trzcinski, Katherine L. O'Brien, Daniela M. Ferreira, Anne L. Wyllie, Daniel Weinberger, Leon Danon, Stephen I. Pelton, Chiara Azzari, Laura L. Hammitt, Raquel Sa-Leao, Maria-Cristina C. Brandileone, Samir Saha, Jose Suaya, Raul Isturiz, Luis Jodar, Bradford D. Gessner
EXPERT REVIEW OF VACCINES
(2020)
Review
Immunology
Silvia Ricci, Chiara Azzari, Emanuele Amodio, Paolo Castiglia
Summary: In Italy, vaccination against serogroup B is recommended for infants aged 3-13 months, serogroup C for infants aged 13-15 months, and serogroups A, C, Y, and W for adolescents aged 12-18 years. A quadrivalent meningococcal conjugate vaccine, MenACYW-TT (MenQuadfi; Sanofi), is recommended based on its high seroprotection rates and low incidence of adverse events in these age groups.
EXPERT REVIEW OF VACCINES
(2023)
Article
Pediatrics
Federica Barbati, Edoardo Marrani, Beatrice Volpi, Giovanna Ferrara, Lorenzo Lodi, Maria Vincenza Mastrolia, Clementina Canessa, Ilaria Maccora, Gabriele Simonini, Chiara Azzari, Silvia Ricci
Summary: This study found that pediatric patients with chronic rheumatic diseases receiving MMF treatment may experience a decrease in immunoglobulin levels, leading to an increased risk of infections. It is recommended to conduct immunological tests and serological analyses before starting immunosuppressive drug therapy to prevent infections, and to continuously monitor immunoglobulin levels during and after treatment.
EUROPEAN JOURNAL OF PEDIATRICS
(2022)
Article
Health Care Sciences & Services
C. Azzari, V Baldo, S. Giuffrida, R. Gani, E. O'Brien, C. Alimenti, V. J. Daniels, L. J. Wolfson
CLINICOECONOMICS AND OUTCOMES RESEARCH
(2020)
Article
Genetics & Heredity
Annalisa Vetro, Tiziana Pisano, Silvia Chiaro, Elena Procopio, Azzurra Guerra, Elena Parrini, Davide Mei, Simona Virdo, Giusi Mangone, Chiara Azzari, Renzo Guerrini
NEUROLOGY-GENETICS
(2020)